SCHEMBL713902

SCHEMBL713902

COC(=O)CCCN(C)C

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.64
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
DNM1 Q05193 1/20 0.46
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
PAOX Q6QHF9 1/20 0.42
KDM5A P29375 3/20 0.42
KDM4A O75164 5/20 0.41
KDM4C Q9H3R0 5/20 0.41
KDM7A Q6ZMT4 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
LTA4H P09960 1/20 0.41
CA12 O43570 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1671482 0.98 MEN1 (0.61) TSHRMEN1KMT2ADNM1ALDH1A1
SCHEMBL10084980 0.93 TSHR (0.61) TSHRMEN1KMT2ADNM1ALDH1A1
SCHEMBL18556504 0.91 TSHR (0.58) TSHRMEN1KMT2ADNM1ALDH1A1
SCHEMBL711981 0.91 TSHR (0.58) TSHRMEN1KMT2ADNM1ALDH1A1
SCHEMBL25181649 0.90 TSHR (0.52) TSHRMEN1KMT2ADNM1ALDH1A1
SCHEMBL14430424 0.86 MEN1 (0.71) TSHRMEN1KMT2ADNM1ALDH1A1
SCHEMBL215293 0.85
SCHEMBL31647713 0.83 DNM1 (0.47) TSHRMEN1KMT2ADNM1ALDH1A1
Hydrochloric Acid SCHEMBL12488733 0.83 KMT2A (0.74) TSHRMEN1KMT2ADNM1ALDH1A1
Hydrochloric Acid SCHEMBL4390740 0.83 KMT2A (0.74) TSHRMEN1KMT2ADNM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098635-A1 NEW CATIONIC LIPID WITH NITROGEN-CONTAINING HETEROCYCLIC HEAD GROUP AND USE THEREOF 厦门赛诺邦格生物科技股份有限公司 2026-05-15 WO claimed
CN-118955655-A GE protein antigen variant, preparation method and application thereof 北京微星生物科技有限公司 2024-11-15 CN claimed
WO-2024078534-A1 INTERFERING RNA FOR INHIBITING EXPRESSION OF MELANOPHILIN (MLPH) GENE, AND APPLICATION THEREOF 北京键凯科技股份有限公司 2024-04-18 WO claimed
CN-116322788-A Cyclic RNA compositions and methods 奥纳治疗公司 2023-06-23 CN claimed
WO-2023081494-A2 NUCLEOSIDE MODIFIED MRNA AND USES THEREOF BOSTON MEDICAL CENTER CORPORATION (US) 2023-05-11 WO claimed
CN-115803049-A Antigen encoding cassette 磨石生物公司 2023-03-14 CN claimed
CN-113151312-B Novel coronavirus SARS-CoV-2mRNA vaccine and its preparation method and application 中国科学院微生物研究所 2022-12-09 CN claimed
CN-114272369-A mRNA vaccine composition for preventing varicella-zoster virus 中国科学院微生物研究所 2022-04-05 CN claimed
EP-3364950-A1 TROPICAL DISEASE VACCINES ModernaTX, Inc. (US) 2018-08-29 EP claimed
EP-3364949-A1 CANCER VACCINES ModernaTX, Inc. (US) 2018-08-29 EP claimed
US-9278907-B2 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease JSC GRINDEKS (LV) 2016-03-08 US claimed
US-8940793-B2 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease JSC GRINDEKS (LV) 2015-01-27 US claimed
EP-2491005-B1 USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE GRINDEKS JSC (LV) 2014-07-23 EP claimed
US-20140107202-A1 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease JSC GRINDEKS (LV) 2014-04-17 US claimed
EP-2702037-A1 4-[(HALOALKYL)(DIMETHYL)AMMONIO]BUTANOATES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISEASE Grindeks, A Joint Stock Company (LV) 2014-03-05 EP claimed
WO-2012146737-A1 4-[(HALOALKYL)(DIMETHYL)AMMONIO]BUTANOATES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISEASE GRINDEKS, A JOINT STOCK COMPANY (LV) 2012-11-01 WO claimed
US-20120220656-A1 USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE JSC GRINDEKS (LV) 2012-08-30 US claimed
EP-2491005-A1 USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE Grindeks, A Joint Stock Company (LV) 2012-08-29 EP claimed
WO-2011048201-A1 USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE GRINDEKS, A JOINT STOCK COMPANY (LV) 2011-04-28 WO claimed
CN-1289249-A Derivatives of 1,3,4-oxadiazolone BRISTOL MYERS SQUIBB CO (US) 2001-03-28 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107202-A1 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease FABP3, HCN3, HCN4 TSHR 2698/4885MEN1 3768/4885KMT2A 1305/4885
US-20120220656-A1 USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE FABP3, ABAT, BBOX1 TSHR 4548/4885MEN1 3008/4885KMT2A 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.